We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Pfizer Inc. closed 26.70% short of its 52-week high of $31.54, which the company achieved on July 30th.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Kindler and his wife, Sharon Sullivan, who works in the performing arts, have listed a four-bedroom, four-bath condo on West ...